http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Motoya Suzuki,Shuichi Yahagi 제어로봇시스템학회 2022 제어로봇시스템학회 국제학술대회 논문집 Vol.2022 No.11
Vehicle velocity control has attracted significant research attention for autonomous driving applications. To achieve reliable autonomous driving, the desired velocity control should be realized. However, it is challenging to realize the desired control response because it is difficult to identify the accurate vehicle model. A feedback controller based on the nominal model cannot realize the desired velocity controls when the nominal error is extremely large. In this study, we propose a velocity control based on a model error compensator (MEC) and fictitious reference iterative tuning (FRIT). The proposed method can calculate the control signal to minimize the relative error between the closed-loop system and the normative model. By designing the tunable parameters of the MEC in the framework of FRIT, the desired control response can be achieved using one-shot experimental data. We verified the proposed method using a vehicle dynamics blockset.
Lan Kang,Motoya Suzuki,Hanbin Ge 국제구조공학회 2018 Steel and Composite Structures, An International J Vol.26 No.5
Although a lot of experimental and analytical investigations have been carried out for steel bridge piers made of SS400 and SM490, the formulas available for SS400 and SM490 are not suitable for evaluating ultimate load and deformation capacities of steel bridge piers made of high strength steel (HSS) SM570. The effect of various parameters is investigated in this paper, including plate width-to-thickness ratio, column slenderness ratio and axial compression force ratio, on the ultimate load and deformation capacities of steel bridge box piers made of SM570 steel subjected to cyclic loading. The elasto-plastic behavior of the steel bridge piers under cyclic loads is simulated through plastic large deformation finite element analysis, in which a modified two-surface model (M2SM) including cyclic hardening is employed to trace the material nonlinearity. An extensive parametric study is conducted to study the influences of structural parameters on the ultimate load and deformation capacities. Based on these analytical investigations, new formulas for predicting ultimate load and deformation capacities of steel bridge piers made of SM570 are proposed. This study extends the ultimate load and deformation capacities evaluation of steel bridge piers from SS400, SM490 steels to SM570 steel, and provides some useful suggestions.
Toshifumi Hibi,Satoshi Motoya,Toshifumi Ashida,Souken Sai,Yukinori Sameshima,Shiro Nakamura,Atsuo Maemoto,Masahiro Nii,Barbara A Sullivan,Robert A. Gasser Jr,Yasuo Suzuki 대한장연구학회 2019 Intestinal Research Vol.17 No.3
Background/Aims: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventional treatments. Methods: In this randomized, double-blind, placebo-controlled study, 45 UC patients were randomized to abrilumab 21 mg (n=11), 70 mg (n=12), 210 mg (n=9), or placebo (n=13) via subcutaneous (SC) injection for 12 weeks. The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg SC every 12 weeks, and a 28-week safety follow-up period. The primary efficacy variable was clinical remission at week 8 (total Mayo score ≤2 points with no individual subscore >1 point). Results: Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, fewer patients in the abrilumab groups experienced ≥1 adverse event compared with those in the placebo group. There were no cases of progressive multifocal leukoencephalopathy and no deaths. Conclusions: Abrilumab 70 mg and 210 mg yielded numerically better results in terms of clinical remission rate at Week 8 than placebo, with the 210 mg dose showing more consistent treatment effects. Abrilumab was well tolerated in Japanese patients with UC.
( Tadakazu Hisamatsu ),( Hyo Jong Kim ),( Satoshi Motoya ),( Yasuo Suzuki ),( Yoshifumi Ohnishi ),( Noriyuki Fujii ),( Nobuko Matsushima ),( Richuan Zheng ),( Colleen W. Marano ) 대한장연구학회 2021 Intestinal Research Vol.19 No.4
Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with mod-erate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data from East-Asian patients included in the UNIFI program (NCT02407236). UNIFI consisted of two double-blind, placebo-controlled trials: an 8-week induction study and a 44-week randomized withdrawal maintenance study. Results: Of 133 East-Asian patients (Japanese: 107, Korean: 26) who underwent randomization, 131 completed induction study and 111 entered maintenance study. In the main-tenance study, 78 patients were randomized. Patients who received UST 130 mg and UST 6 mg/kg showed numerically higher clinical remission at week 8 in the induction study (5/44 [11.4%] and 5/45 [11.1%], respectively) compared with those who re-ceived placebo (0/44, 0%). The proportion of patients achieved clinical remission at week 44 was numerically higher in the UST 90 mg q12w group (10/21, 47.6%), but similar in the UST 90 mg q8w group (5/26, 19.2%) compared to placebo (7/31, 22.6%). Serious adverse events were reported in 1 patient in UST 130 mg group, but no patient in UST 6 mg/kg group through week 8 in the induction study, and 1 patient in UST 90 mg q12w group and 5 patients in the UST 90 mg q8w group in the maintenance study. No deaths were reported in East-Asian patients throughout the study. Conclusions: UST induction and maintenance treatments were effective in East-Asian patients with moderate to severe UC; the efficacy and safety profiles were consistent with the overall population. (Intest Res 2021;19:386-397)